STAAR Surgical Company Stock Deutsche Boerse AG

Equities

SR3

US8523123052

Medical Equipment, Supplies & Distribution

Market Closed - Deutsche Boerse AG 02:05:14 2024-07-12 am EDT 5-day change 1st Jan Change
43.4 EUR +2.75% Intraday chart for STAAR Surgical Company +9.02% +50.22%
Sales 2024 * 340M 312M Sales 2025 * 395M 362M Capitalization 2.31B 2.12B
Net income 2024 * - 0 Net income 2025 * 18M 16.51M EV / Sales 2024 * 6.12 x
Net cash position 2024 * 232M 213M Net cash position 2025 * 240M 220M EV / Sales 2025 * 5.26 x
P/E ratio 2024 *
-
P/E ratio 2025 *
114 x
Employees 1,057
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.48%
More Fundamentals * Assessed data
Dynamic Chart
STAAR Surgical Company Provides Information to the Shareholders CI
Transcript : STAAR Surgical Company Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 08:00 AM
BTIG Upgrades STAAR Surgical to Buy From Neutral, Price Target is $46 MT
Mizuho Adjusts STAAR Surgical's Price Target to $55 From $53, Keeps Buy Rating MT
Morgan Stanley Raises Price Target on STAAR Surgical to $50 From $35, Keeps Equalweight Rating MT
Transcript : STAAR Surgical Company, Q1 2024 Earnings Call, May 07, 2024
STAAR Surgical Company Reports Earnings Results for the First Quarter Ended March 29, 2024 CI
STAAR Surgical Company Reiterates Earnings Guidance for the Fiscal Year 2024 CI
STAAR Surgical Company Surgical Announces Milestone Strategic Agreement in U.S. with IQ Laser Vision CI
STAAR Surgical Strengthens Leadership Team with Appointments of Nancy Sabin as Chief Marketing Officer and Nathaniel Sisitsky as General Counsel CI
Mizuho Adjusts Price Target on STAAR Surgical to $53 From $45, Maintains Buy Rating MT
Canaccord Genuity Raises Price Target on STAAR Surgical to $46 From $32, Maintains Hold Rating MT
STAAR Surgical Shares Jump After Reporting Preliminary Fiscal Q1 Sales MT
Sector Update: Health Care Stocks Lean Higher Pre-Bell Thursday MT
STAAR Surgical Reports Preliminary Fiscal Q1 Sales; Updates Fiscal 2024 Sales Outlook -- Shares Jump Pre-Bell MT
More news
1 day+2.75%
1 week+9.02%
Current month-0.18%
1 month+21.03%
3 months-9.55%
6 months+45.25%
Current year+50.22%
More quotes
1 week
38.12
Extreme 38.12
43.40
1 month
37.20
Extreme 37.2
44.04
Current year
25.60
Extreme 25.6
47.99
1 year
25.60
Extreme 25.6
51.86
3 years
25.60
Extreme 25.6
137.30
5 years
21.60
Extreme 21.6
137.30
10 years
4.44
Extreme 4.441
137.30
More quotes
Managers TitleAgeSince
Chief Executive Officer 68 20-05-31
Director of Finance/CFO 51 20-07-05
Chief Operating Officer 48 23-04-23
Members of the board TitleAgeSince
Director/Board Member 59 15-12-31
Director/Board Member 55 22-06-15
Chief Executive Officer 68 20-05-31
More insiders
Date Price Change
24-07-12 43.4 +2.75%
24-07-11 42.24 +10.81%
24-07-10 38.12 -3.74%
24-07-09 39.6 -4.88%
24-07-08 41.63 +4.57%

Delayed Quote Deutsche Boerse AG, July 12, 2024 at 02:05 am EDT

More quotes
STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. These lenses provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. The Company is a manufacturer of lenses used worldwide in corrective or refractive surgery. It sells its products in approximately 75 countries, with direct distribution in Japan, Germany, Spain, the United States, Canada, the United Kingdom, and Singapore, with a combination of direct distribution and independent distribution in China, Korea, India, France, Benelux, and Italy. The Company markets and sells ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. The Company’s EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company also markets and sells an ICL lens to treat hyperopia (farsightedness), which is called Visian ICL.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
47.11 USD
Average target price
51.77 USD
Spread / Average Target
+9.89%
Consensus